Key points (5).
• From a wide set of integrated data, larotrectinib has demonstrated an elevated efficiency in diverse tumors, achieving 81% ORR and a complete response of 17%. • Of the patients with NTRK fusions treated with larotrectinib, 9% required a reduction of the dose. All maintained a tumor regression. • Less than 1% of the patients with NTRK fusion suspended larotrectinib due to the presentation of an adverse event. |